Abstract: Studies on trabecular bone score (TBS) in psoriasis are lacking. We aim to assess the association between TBS and inflammation,
metabolic syndrome features, and serum adipokines in 29 nondiabetic patients with psoriasis without arthritis, before and after
6-month adalimumab therapy. For that purpose, adjusted partial correlations and stepwise multivariable linear regression analysis
were performed. No correlation was found between TBS and disease severity. TBS was negatively associated with weight, BMI,
waist perimeter, fat percentage, and systolic and diastolic blood pressure before and after adalimumab. After 6months of therapy, a
negative correlation between TBS and insulin resistance (?? = 0.02) and leptin (?? = 0.01) and a positive correlationwith adiponectin
were found (?? = 0.01).The best set of predictors for TBS values at baseline were female sex (?? = 0.015), age (?? = 0.05), and BMI
(?? = 0.001). The best set of predictors for TBS following 6 months of biologic therapy were age (?? = 0.001), BMI (?? < 0.0001), and
serumadiponectin levels (?? = 0.027). In conclusion, in nondiabetic patients withmoderate-to-severe psoriasis, TBS correlates with
metabolic syndrome features and inflammation.This association is still present after 6 months of adalimumab therapy. Moreover,
serum adiponectin levels seem to be an independent variable related to TBS values, after adalimumab therapy.
Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria
Fuente: Journal of Osteoporosis Volume 2016, Article ID 5747852
Editorial: Hindawi Publishing Corporation
Año de publicación: 2016
Nº de páginas: 7
Tipo de publicación: Artículo de Revista
DOI: 10.1155/2016/5747852
ISSN: 2090-8059,2042-0064